Cancer drug discovery Archives
Clinical study tests drug that may prevent cancer metastasis
Jul. 8, 2019—A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.
Cancer’s SOS
Mar. 28, 2019—Stephen Fesik and colleagues are advancing cancer drug discovery with the characterization of small molecules that modulate RAS, an important target for anti-cancer therapies.
STINGing combination for cancer
Jun. 19, 2017—A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer.
Improving therapies for GI tumors
Feb. 20, 2017—A signaling protein overexpressed in upper gastrointestinal cancers is an attractive therapeutic target.
Kleberg Foundation grant bolsters cancer drug discovery efforts
Aug. 3, 2016—The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation has awarded a $3 million grant to Vanderbilt-Ingram Cancer Center (VICC) investigators in support of VICC’s drug discovery program. The gift awarded over the next three years from the private, San Antonio, Texas-based foundation will enable VICC researchers to pursue the development of new compounds to block the activity of cancer-causing genes and proteins that had previously been considered “undruggable.”
VU takes key role in cancer drug discovery consortium
Jun. 23, 2016—Vanderbilt University has been selected as one of seven Dedicated Centers in the nation for the next phase of the Chemical Biology Consortium (CBC), a national network of scientists on the leading edge of cancer drug discovery.
Current cancer drug discovery method flawed: VUMC study
May. 5, 2016—The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers reported May 2 in Nature Methods.
Anticancer olive compounds
Jul. 27, 2015—Compounds found in olives and olive oil have anticancer activity, which may contribute to the cancer preventive properties attributed to the Mediterranean diet.
Micelle “packets” deliver cancer drugs
Apr. 8, 2015—Vanderbilt researchers designed micelle “packets” to selectively deliver anti-cancer drugs to breast cancer cells.
Cancer signaling pathway blocker
Apr. 3, 2015—Researchers at Vanderbilt University have discovered a new way to inhibit Hedgehog (Hh) signaling, an important regulatory pathway for vertebrate development – and cancer.
Antibiotics with anticancer potential
Feb. 25, 2015—A series of experimental antibiotics may be a good starting point for developing new anticancer drugs.
New insight on oral cancer culprits
Nov. 12, 2014—A new mouse model offers insight into the signaling pathways that control oral cancers – and a platform for testing anticancer therapeutics.
